• KOL
    • Atopic Dermatitis
    • Amy S Paller
    • Amy S Paller: Influence Statistics

      Amy S Paller

      Amy S Paller

      Show email address

      Northwestern Memorial Hospital | Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA | Department of ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Amy S Paller:Expert Impact

      Concepts for whichAmy S Pallerhas direct influence:Atopic dermatitis,Pediatric patients,Epidermolysis bullosa,Pediatric psoriasis,United states,Tacrolimus ointment,Dermatitis atopic,Atopic eczema.

      Amy S Paller:KOL impact

      Concepts related to the work of other authors for whichfor which Amy S Paller has influence:Atopic dermatitis,Epidermolysis bullosa,Skin diseases,Food allergy,Topical corticosteroids,Wound healing,Tacrolimus ointment.

      KOL Resume for Amy S Paller

      Year
      2022

      Northwestern Memorial Hospital

      2021

      Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611.

      Ann and Robert H. Lurie Children’s Hospital, Chicago, IL USA

      Northwestern University, Evanston, Illinois.

      Center for Bio-Integrated Electronics, Evanston, Illinois

      2020

      Department of Dermatology, Northwestern University, Chicago, Illinois, 60611, United States

      Northwestern University/aff

      2019

      Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611

      Northwestern University Feinberg Medical School, Chicago, Illinois. Electronic address:

      Department of Pediatrics, Division of Dermatology, Ann Robert H. Lurie Children's Hospital, Chicago, IL, USA

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Amy S Paller is among the top experts in the world.
      Concept World rank
      biologics rcts #1
      dx308 shortcomings #1
      gt1b #1
      ifn psmb8 #1
      treatment head neck #1
      topical cholesterol lovastatin #1
      majority pediatric dermatologists #1
      pediatric patients natural #1
      pediatric psoriasis comorbidities #1
      sleep disturbance methods #1
      children knuckle pads #1
      treatment 1 aes #1
      respondents systemic corticosteroids #1
      attention regulation sleep #1
      pediatric patients methotrexate #1
      24 treatment success #1
      igf1r endocytosis #1
      keratinocyte interaction fibronectin #1
      1 aes #1
      sleep disturbance itch #1
      illness ichthyosis ichthyosis #1
      gm3 depletion phosphorylation #1
      individuals ichthyosis #1
      300 q4w patients #1
      ichthyosis participants #1
      terms eczema #1
      eczema control views #1
      inherited ichthyoses sorèze #1
      6 months biologics #1
      16 participants bsi #1
      wounds methicillin resistance #1
      patients ichthyoses #1
      gastrointestinal endoscopy biopsies #1
      differentiation cultured gm3 #1
      ichthyosiform erythroderma disorders #1
      gt1b gd3 #1
      ser473 site #1
      lesional tissue activation #1
      clathrin flot1 #1
      dx308 vitro assessment #1
      1 aes methotrexate #1
      dermatitis 3 #1
      nonsteroidal child dermatitis #1
      omenn syndrome case #1
      antigt1b antibody #1
      united states iga×bsa #1
      ustekinumab moderatetosevere psoriasis #1
      interrater reliabilities scale #1
      infant pruritus quality #1
      pkcalpha suppression #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Amy S Paller

      KOL-Index: 35767

      BACKGROUND: Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, and tyrosine kinase 2. We aimed to assess the efficacy and safety of upadacitinib compared with placebo for the treatment of moderate-to-severe atopic dermatitis.

      METHODS: Measure Up 1 and Measure Up 2 were replicate multicentre, randomised, double-blind, placebo-controlled, phase 3 trials; Measure Up 1 was done at 151 clinical centres in 24 countries across Europe, ...

      Known for Patients Upadacitinib | Atopic Dermatitis | 30 Placebo | 1 Measure | Phase 3
      KOL-Index: 17900

      Importance: Adolescents with atopic dermatitis (AD) have high disease burden negatively affecting quality of life, with limited treatment options. The efficacy and safety of dupilumab, a monoclonal antibody, approved for treatment in adolescent patients with inadequately controlled AD, remain unknown in this patient population.

      Objective: To assess the efficacy and safety of dupilumab monotherapy in adolescents with moderate to severe inadequately controlled AD.

      Design, Setting, and ...

      Known for Dupilumab Adolescents | 2 Weeks | Efficacy Safety | Severe Atopic | Quality Life
      KOL-Index: 16808

      BACKGROUND: Plaque psoriasis affects children and adults, but treatment options for paediatric psoriasis are limited.

      OBJECTIVES: To evaluate the efficacy and safety of ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin-17A, for moderate-to-severe paediatric psoriasis.

      METHODS: In a randomized, double-blind, placebo-controlled, phase III study (IXORA-PEDS), patients aged 6 to < 18 years with moderate-to-severe plaque psoriasis were randomized 2 : 1 ...

      Known for Paediatric Patients | Ixekizumab Ixe | Severe Plaque | Efficacy Safety | Treatment Moderate
      KOL-Index: 15057

      BACKGROUND: Children with severe atopic dermatitis (AD) have limited treatment options.

      OBJECTIVE: We report the efficacy and safety of dupilumab + topical corticosteroids (TCS) in children aged 6-11 years with severe AD inadequately controlled with topical therapies.

      METHODS: In this double-blind, 16-week, phase 3 trial (NCT03345914), 367 patients were randomized 1:1:1 to 300 mg dupilumab every 4 weeks (300 mg q4w), a weight-based regimen of dupilumab every 2 weeks (100 mg q2w, baseline ...

      Known for Severe Atopic Dermatitis | Dupilumab Tcs | Efficacy Safety | Topical Corticosteroids | 11 Years
      KOL-Index: 13686

      BACKGROUND: Identifying differences and similarities between cutaneous lymphocyte antigen (CLA)(+) polarized T-cell subsets in children versus adults with atopic dermatitis (AD) is critical for directing new treatments toward children.

      OBJECTIVE: We sought to compare activation markers and frequencies of skin-homing (CLA(+)) versus systemic (CLA(-)) "polar" CD4 and CD8 T-cell subsets in patients with early pediatric AD, adults with AD, and control subjects.

      METHODS: Flow cytometry was ...

      Known for Children Adults | Early Pediatric | Atopic Dermatitis | Cutaneous Lymphocyte Antigen | Th1 Cell
      KOL-Index: 13622

      The interaction of the urokinase-type plasminogen activator (uPA) receptor (uPAR) with integrins plays a critical role in the regulation of cell adhesion and migration. However, the molecular events underlying the modulation of the interaction of uPAR and integrin are poorly understood. Gangliosides are thought to regulate epithelial cell adhesion and migration by inhibiting alpha(5)beta(1) integrin and epidermal growth factor receptor (EGFR) signaling. We report here that increases in ...

      Known for Upa Receptor | Cell Migration | Plasminogen Activator | Focal Adhesion | Epidermal Growth Factor
      KOL-Index: 13340

      BACKGROUND: Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids.

      OBJECTIVES: To evaluate the efficacy and safety of baricitinib in patients with moderate-to-severe AD who had an inadequate response to topical therapies.

      METHODS: In two independent, multicentre, double-blind, phase III monotherapy trials, BREEZE-AD1 and BREEZE-AD2, adults with moderate-to-severe AD ...

      Known for Inadequate Response | Topical Corticosteroids | Baricitinib Patients | Atopic Dermatitis | 1 2
      KOL-Index: 13295

      BACKGROUND: Etanercept, a soluble tumor necrosis factor receptor, has been shown to lessen disease severity in adult patients with psoriasis. We assessed the efficacy and safety of etanercept in children and adolescents with moderate-to-severe plaque psoriasis.

      METHODS: In this 48-week study, 211 patients with psoriasis (4 to 17 years of age) were initially randomly assigned to a double-blind trial of 12 once-weekly subcutaneous injections of placebo or 0.8 mg of etanercept per kilogram ...

      Known for Plaque Psoriasis | Etanercept Treatment | Placebo Pasi | Children Adolescents | 24 Weeks
      KOL-Index: 13286

      BackgroundAtopic dermatitis is a chronic inflammatory condition with substantial burden and limited treatment options for adolescents with moderate-to-severe disease. Significantly more patients treated with dupilumab vs. placebo achieved Investigator’s Global Assessment 0/1 at week 16.ObjectiveThe objective of this study was to assess the impact of dupilumab treatment vs. placebo on the achievement of clinically meaningful improvements in atopic dermatitis signs, symptoms and quality of ...

      Known for Atopic Dermatitis | Quality Life | Dupilumab Placebo | Signs Symptoms | Clinically Meaningful
      KOL-Index: 12985

      BACKGROUND: Additional topical treatments for atopic dermatitis (AD) are needed that provide relief while minimizing risks.

      OBJECTIVE: We sought to assess the efficacy and safety of crisaborole ointment, a phosphodiesterase 4 inhibitor, in two phase III AD studies (AD-301: NCT02118766; AD-302: NCT02118792).

      METHODS: Two identically designed, vehicle-controlled, double-blind studies enrolled and randomly assigned (2:1, crisaborole:vehicle) patients aged 2 years or older with an ...

      Known for Crisaborole Ointment | Topical Treatment | Isga Score | Heterocyclic Child Child | Efficacy Safety
      KOL-Index: 12737

      Importance: Children with epidermolysis bullosa (EB) comprise a rare population with high morbidity and mortality. An improved understanding of the clinical trajectory of patients with EB, including age at time of clinical diagnosis and major clinical events, is needed to refine best practices and improve quality of life and clinical outcomes for patients with EB.

      Objectives: To describe demographics, clinical characteristics, milestone diagnostic and clinical events (such as initial ...

      Known for Epidermolysis Bullosa | Patients Eb | Clinical Characteristics | Diagnostic Testing | Genetic Analysis
      KOL-Index: 12426

      The autosomal recessive disorder lipoid proteinosis results from mutations in extracellular matrix protein 1 (ECM1), a glycoprotein expressed in several tissues (including skin) and composed of two alternatively spliced isoforms, ECM1a and ECM1b, the latter lacking exon 7 of this 10-exon gene (ECM1). To date, mutations that either affect ECM1a alone or perturb both ECM1 transcripts have been demonstrated in six cases. However, lipoid proteinosis is clinically heterogeneous with affected ...

      Known for Lipoid Proteinosis | Extracellular Matrix | Protein 1 | Mutations Exon | Skin Scarring
      KOL-Index: 12204

      Importance: Interleukin 13 (IL-13) is a central pathogenic mediator driving multiple features of atopic dermatitis (AD) pathophysiology.

      Objective: To evaluate the efficacy and safety of lebrikizumab, a novel, high-affinity, monoclonal antibody targeting IL-13 that selectively prevents formation of the IL-13Rα1/IL-4Rα heterodimer receptor signaling complex, in adults with moderate to severe AD.

      Design, Setting, and Participants: A phase 2b, double-blind, placebo-controlled, dose-ranging ...

      Known for 2 Weeks | Severe Atopic | Monoclonal Dermatitis | Safety Lebrikizumab | Placebo Patients
      KOL-Index: 12029

      The epidermal growth factor receptor (EGFR) can be activated by both direct ligand binding and cross-talk with other molecules, such as integrins. This integrin-mediated cross-talk with growth factor receptors participates in regulating cell proliferation, survival, migration, and invasion. Previous studies have shown that ligand-dependent EGFR activation is inhibited by GM3, the predominant ganglioside of epithelial cells, but the effect of GM3 on ligand-independent, integrin-EGFR ...

      Known for Ganglioside Gm3 | Integrin Egfr | Growth Factor | Cell Proliferation | Focal Adhesion

      Key People For Atopic Dermatitis

      Top KOLs in the world
      #1
      Donald Y M Leung
      atopic dermatitis eczema herpeticum food allergy
      #2
      Thomas RM Bieber
      atopic dermatitis dendritic cells lupus erythematosus
      #3
      Jon M Hanifin
      atopic dermatitis eczema herpeticum histamine release
      #4
      Mark Boguniewicz
      atopic dermatitis eczema herpeticum tacrolimus ointment
      #5
      Hywel C G Williams
      atopic eczema cochrane skin basal cell carcinoma
      #6
      Johnannes Ring
      atopic eczema west germany histamine release

      Northwestern Memorial Hospital | Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA | Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.